



**BioLight Life Sciences Ltd.
(The "Company")**

August 16, 2023

Re: OPHRX Ltd. (Subsidiary) receives positive results in the clinical trial

The Company is honored to announce that OphRx, Ltd. ("OphRx") a subsidiary of the Company has informed the Company that it has received the final results of its human clinical trial involving eye drops based on its delivery technology containing the active ingredient Cyclosporine at two higher concentrations compared to the market-leading product, which is at lower concentration (the 'Trial').

As informed by OphRx, the two higher concentrations demonstrated a similar level of comfort for the participants in a statistically significant manner (non-inferiority) according to the primary endpoint of the Trial, when compared to the market leader product currently used in the market. The Trial was conducted at Jerusalem's Shaare Zedek Medical Center and included 20 healthy participants.

OphRx considers the higher concentration to have the potential to shorten the clinical onset of effects and therefore improve outcomes for dry eye patients. This higher concentration may also be suitable for patients with severe dry eye symptoms, as well as for addressing other front-of-the-eye diseases

The trial was conducted at Jerusalem's Shaare Zedek Hospital, which included 20 healthy participants.

OphRx regards the higher concentration as a potential to shorten the time relief is attained and improved for dry eye patients in addition to the possibility that the product may be suitable for patients with severe dry eye symptoms as well as for additional front of the eye diseases.

About OphRx

OphRx a subsidiary company of the Company, is engaged in the development of drugs for the treatment of eye diseases through an innovative technological platform that enhances the transmission of ocular substances based on nanostructures.

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects in the field of eye diseases and ocular treatments. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine designed to improve the efficacy and safety of treatments of eye diseases exemplifying the enormous potential of Israeli innovation in these fields.